Physician profile
Mariette Pierre
NPI 1972542124
$4,730.34
in general payments reported to CMS, 2019-2025
21 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $404 · 2021: $581 · 2022: $592 · 2023: $637 · 2024: $1,194 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,955 · Education: $13.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,955.00 |
| Education | $13.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,252.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $861.67 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $592.60 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.31 | 2020-2025 | Jardiance |
| Amgen INC. | $292.03 | 2024-2025 | Evenity, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $274.65 | 2022-2024 | |
| Abbott Laboratories | $245.72 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $157.80 | 2021-2025 | |
| Abbvie INC. | $124.69 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $121.86 | 2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $55.65 | 2020-2021 | |
| Exact Sciences Corporation | $47.00 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $43.19 | 2023 | Spravato |
| Astellas Pharma US INC | $40.71 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $37.07 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36.66 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.96 | 2019 | |
| Glaxosmithkline, LLC. | $22.25 | 2024 | Trelegy Ellipta, Arexvy |
| Currax Pharmaceuticals LLC | $14.62 | 2023 | Contrave |
| Tactile Systems Technology INC | $14.41 | 2019 | |
| Amarin Pharma, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariette Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.